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ABSTRACT
Objective: Systemic bioavailability of metoclopramide hydrochloride (MCH) is 32–80% by oral route. The study was targeted to develop in situ gel of 
MCH for nasal delivery and to study its pharmacokinetics in healthy rabbits. Pre-systemic metabolism can be overcome.
Methods: Poloxamer 407 (P407) aqueous solutions were prepared by cold method. In 32 factorial design, independent variables were Carbopol 
934P (C934P) and polyethylene glycol 6000 (PEG 6000), and dependent responses were gelation temperature, mucoadhesive strength, and drug 
release. A Pharmacokinetic study was carried out in New Zealand rabbits. The optimized in situ gel (1 mg/ml) was compared with marketed Reglan® 
(2 mg/2 ml) injection. 
Results: F2 was an optimized formulation. The study showed that P407 solutions formed a gel at nasal temperature 34°C having mucoadhesive 
strength 807.12±3.45 dyne/cm2. MCH release was found to be 93.74±1.31% within 6 h. Histopathological examination of formulation F2 exhibited 
safety to the nasal mucosa. The pH of formulations was 5.1±0.1 to 5.6±0.1 in the range of pH of nasal cavity. Plasma samples were analyzed by liquid 
chromatography/mass spectroscopy (LC/MS). The area under curve AUC0-4 for in situ gel by nasal route was 2716±4.62 ng.h/ml and for marketed 
solution by intravenous route was 2874±1.08 ng.h/ml. These were comparable. Nasal bioavailability was found 94.50% from in situ gel. Duration of 
action was longer, and steady-state concentration was found for in situ gel.
Conclusion: In situ gel was capable to release MCH in systemic circulation. In vivo study in rabbits has proved the improved bioavailability of MCH 
administered nasally. The optimized gel preparation was found to be promising for improved bioavailability.
Keywords: Antiemetic, Mucoadhesive, Nasal, Poloxamer 407, Thermoreversible.
INTRODUCTION
Metoclopramide hydrochloride (MCH) is a potent antiemetic. It is 
effective in the treatment of nausea and vomiting usually occurred 
with migraine, cancer therapy, and pregnancy. Although it is used 
in this treatment, it has oral bioavailability 32–80% due to large 
pre-systemic metabolism [1]. Although parenteral administration is 
recommended over oral, it has low patient compliance. On the other 
hand, oral doses are likely to get vomit before its systemic absorption. 
In such a situation, intranasal delivery would be the best alternative. 
However, low residence time of drug is a limitation of the nasal route. 
This may affect bioavailability of a drug. Hence, the dosage form 
or delivery system should be designed in such a way that it should 
overwhelmed the limitations by considering anatomical as well as 
physiological features of nasal cavity. This should ultimately result in a 
little or no any mucocilliary clearance of administered preparation [2]. 
Hence, mucoadhesive formulations can help the formulator to extend 
the residence time due to their adhesive property. This improves the 
possibility of getting more bioavailability of drug for local and systemic 
effects [3]. Normally pharmaceutical gels are viscous preparations 
being more semisolid in nature creates difficulty in administration into 
a nasal cavity. On the other hand, mucoadhesive powders, although 
can be sprinkled on nasal mucosa, are not favored by one or the other 
reason. They may give a gritty feel with or without irritation. To way out 
the situation, a mucoadhesive in situ gel appears promising approach 
in the hands of formulator. This is due to its liquid nature during 
administration in the form of a drop and viscous nature immediate after 
reaching to the site of nasal mucosa.
Poloxamer 407 (P407) is well-known polymer having thermosensitive 
gelling properties with low toxicity and irritation, water solubility 
at low temperature, and compatibility with other chemicals. In 
addition, it has also good drug release characteristics. It is an ABA 
triblock copolymer of the hydrophilic polyethyleneoxide unit and the 
hydrophobic polypropyleneoxide unit [4]. The polymer exists as a 
mobile viscous liquid at low temperatures, however, forms a semisolid 
gel with an increase in a temperature.
The rationale of the present work is to avoid first pass metabolism 
by non-invasive route thereby improving the bioavailability of 
MCH. Therefore, the objective of the present study was to develop a 
thermosensitive mucoadhesive in-situ gel which would enhance nasal 
residence time of MCH and absorption of MCH across the nasal mucosa. 
Therefore, a pharmacokinetic study was investigated by using such a 
gel in New Zealand rabbits.
MATERIALS AND METHODS
Materials
MCH was kindly gifted by Leben Lab. Pvt., Ltd. Akola, India. P407 was 
kindly provided by BASF, Mumbai, India, and Carbopol 934P (C934P) 
from Ranq Remedies, Thane, India.
Method
Preparation of mucoadhesive in situ gel
P407 (19% w/v) and MCH equivalent to 10 mg were solubilized 
in distilled water containing PEG 6000. This was left at 4–6°C 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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until a clear solution was obtained. In that, C934P was added with 
continuous stirring and again kept for overnight, and then, sorbitol and 
benzalkonium chloride were added and prepared formulation which 
was stored in cool place and evaluated for different parameters [5].
Formulation optimization
A 32 factorial design [6] was applied to the formulation that showed the 
satisfactory gelation temperature (GT), mucoadhesive strength, and in 
vitro drug release to see the effect of varying concentration of C934P 
(X1) and PEG 6000 (X2) on various responses, i.e., GT(Y1), mucoadhesive 
strength (Y2), and percent drug release (Y3). In this design, there were 
two variables and three levels of each variable.
Evaluation of formulations
A compatibility study was carried out to establish whether any 
chemical interaction exists between drug and excipients used in 
formulation [7]. These studies were carried out using Fourier transform 
infrared spectrometer (FTIR) (4100, JASCO, Japan).
The GT of the aqueous solution of P407 was measured using procedures 
reported by Miller and Doravan [8]. A test tube containing about 2 ml 
of a gel was immersed in a water bath, and temperature was increased 
with increments of 2°C and left to equilibrate for about 5 min at each 
new temperature. The samples were examined for gelation (T1). This is 
the characteristic point of gel where the meniscus of the gel inside the 
test tube does not move even after slanting through 90°.
The pH of formulation was determined by taking 1 ml P407 solution 
and diluted by distilled water to make 25 ml. pH of the resulting solution 
was determined using digital pH meter (Equip-Tronics EQ-610, India).
To determine drug content, a formulation of 1 ml was taken in 10 ml 
volumetric flask, diluted with distilled water to 10 ml. One ml from this 
solution was again diluted with 10 ml of distilled water. Finally, the 
absorbance of prepared solution was measured at 272 nm using UV 
visible spectrophotometer (Shimadzu UV-1800, Japan) [9].
The P407 solution sample was retained in small sample adapter of 
Brookfield programmable RVDV-II+Pro viscometer (Brookfield Eng. 
Lab., Inc. USA) for viscosity estimation. The water circulation jacket 
was managed to buildup the temperature of the sample gradually up to 
40°C [10]. Viscosity at various temperatures was documented.
The mucoadhesive strength was measured in terms of detachment 
stress of the formulation. This was determined using a modification 
of the mucoadhesive strength measuring device used by Choi et al. 
[11] A fresh nasal mucosa of sheep was cut into a section. This was 
mounted on a glass vial fortified with the mucosal side out into glass 
vial. The vials were stored at 36°C for 5 min. The vials were adjusted 
in such a way that the gel was placed between the mucosal sides of 
both vials. The height of vials was adjusted as one vial is connected 
to balance and the other fixed with the P407 gel (0.5 ml). Instead of 
putting physical weights, water from a burette was allowed to trip 
in a beaker drop by drop till the complete detachment of vials. The 
two vials detach as the weight of water increased gradually. This 
assembly was prepared in laboratory. Mucoadhesive strength (dyne/
cm²) was the bare minimum weight of water that detached the two 
vials. Mucoadhesive strength = mg/A where, m is weight required for 
detachment in gram, g is acceleration due to gravity (980 cm/s2), and 
A is area of mucosa exposed.
Ex vivo permeation studies
A fresh nasal mucosa was carefully removed from the nasal cavity of a 
sheep obtained from a local slaughterhouse. By taking utmost care while 
handling, the mucosa was fit in a diffusion cell exposing a permeation 
area of 2.98 cm2. Phosphate buffer pH 6.4 at 34±1°C was added to 
the acceptor chamber. The temperature within the chambers was 
maintained at 34°±1°C throughout the experiment. A time of 20 min of 
pre-incubation was left; pure drug solution and formulation equivalent 
to 10 mg of MCH was placed in the donor chambers of two different 
diffusion cells [12]. At pre-determined time points, 1 ml samples were 
withdrawn from the acceptor compartment, and the same volume was 
replaced with phosphate buffer pH 6.4 after each sampling. This was 
continued till the last sampling that is for a period of 6 h. The samples 
withdrawn were filtered through Whatman filter paper and kept ready 
for analysis. The amount of drug permeated was determined using UV-
visible spectrophotometer at 272 nm using calibration curve where 
linearity range was 2 μg/ml to 10 μg/ml and R2 = 0.9998.
Histopathological evaluation of mucosa
A fresh sheep nasal mucosa was stored in 10% v/v of formalin solution to 
avoid bacterial growth. After removal of unwanted portion from the mucosal 
membrane, it became ready for use. Histological study was carried out on 
fresh sheep nasal mucosa treated with 1 ml optimized gel formulation for 
6 h. After treatment, tissue was cut and stained with eosin. Mucosa treated 
with phosphate buffer pH 6.4 was a negative control. At the same time the 
mucosa treated with isopropyl alcohol was positive control [5]. These tissue 
sections were examined under a light microscope (Motic, DMW-B1-223 
ASC) to detect any harm to the tissues during in vitro permeation.
Design of bioavailability study
New Zealand white strain six male rabbits weighing 1.75–2.5 Kg were 
procured from National Toxicology Centre, Pune. The rabbits were 
housed properly 7 days in animal house with good ventilation and plenty 
of water before the commencement of animal study. For bioavailability 
and pharmacokinetic determination, the study includes administering 
the optimized gel formulation by nasal route and intravenous (i.v.) route. 
The protocol was approved having approval no MCP/IAEC/33/2011 
by the Institutional Animal Ethical Committee of Modern College of 
Pharmacy, Nigdi, Pune. The rabbits fasted for 18 h before and during 
the pharmacokinetic study. The animals were conscious throughout 
the duration of the experiments and were held in rabbit restrainers 
during blood sampling. A 0.1 ml gel (in sol form equivalent to 1 mg 
metoclopramide) was deposited into the right nostril of the rabbits of 
Group 1 using a micropipette inserted 1 cm into the right nostril. Reglan® 
(2 mg/2 ml), the marketed formulation, 1 ml was injected into the 
marginal ear vein of Group 2 [13]. After experimentation, rabbits were 
kindly preserved taking utmost care of them in the animal house.
Sample collection and analysis
Respective formulations were administered to each group as mentioned 
above. The blood samples were withdrawn from ear marginal vein at 
time intervals of 10, 60, 120, 180, and 240 min and collected in EDTA 
tubes to prevent clotting of blood. Further, plasma was separated from 
blood samples by centrifuging at 5000 rpm for 10 min. Plasma samples 
were collected and stored at −20°C untill analysis. Drug concentrations 
in plasma samples were determined using liquid chromatography–
mass spectrometry (LC/MS) method.
Frovatriptan succinate 20 µl was used as an internal standard. This was 
extracted from plasma samples. Extracting solvent was mixture of diethyl 
ether and dichloromethane, 1:1 v/v. A 2 ml was added and mixed then 
centrifuged at 10,000 rpm. After flash precipitation, the supernatant 
was decanted with chilled methanol. All the contents were evaporated 
with the help of nitrogen evaporator at 35°C. Samples were reconstituted 
with 200 µl of mobile phase and used for LC/MS analysis. LC (Shimadzu 
Prominence) with MS detector (API 400 QTR) was used. Analytical column 
C-18, 150 mm × 4.6 mm with 5 µm (Chromatopack), and analyst software 
(Applied Biosciences; AB SCIEX) was used. For plasma, the mobile phase 
was made up of 0.1% formic acid in methanol (organic):ammonium 
acetate buffer 10 Mm (aqueous) in the proportion of 85:15 v/v. The 
flow rate was maintained at 1.0 ml/min at ambient temperature. Study 
samples of plasma were run after extraction. These samples were run 
along with the calibration curve for quantitative analysis.
Pharmacokinetic studies
GraphPad Prism software of version 5.01 was used to estimate 
pharmacokinetic parameters. The area under the curve (AUC), peak 
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plasma concentration (Cmax), and time to attain peak concentration 
(Tmax) were obtained from these plots. These were estimated from the 
study samples (plasma) versus time plot.
RESULTS
Evaluation of formulations
FTIR spectrum of pure drug and optimized batch were obtained. They 
are shown in Fig. 1. All the characteristic peak of MCH were present in 
formulation indicating compatibilities between drug and polymers and 
confirmed that there is no significant change in chemical integrity of drug.
Independent variables and dependent variables with their levels are 
shown in Table 1.
Table 2 shows that formulation having a low level (0.25% w/v) of C934P 
showed lower GT, whereas formulation having a high level of C934P 
(0.75% w/v) showed higher GT. It indicates that the mucoadhesive 
polymer used, i.e., C934P had significant effect on GT, and addition 
of water-soluble PEG 6000 produces an increase in GT. The response 
surface plot studied for GT(Y1) is depicted in Fig. 2a.
Results of mucoadhesion test are shown in Table 2. These results indicate 
that C934P (X1) and PEG 6000 (X2) both have effect on mucoadhesive 
strength. As the level of C934 P increases, the mucoadhesive strength 
increases, and as the level of PEG 6000 increases, the mucoadhesive 
strength decreases. The response surface plot studied for the response 
(Y2), i.e., mucoadhesive strength Fig. 2b shows significant effect of 
variables on the response (Y2). The pH of all formulation was found in 
the range of 5.1±0.1 to 5.6±0.1 which lies in the nasal pH range 4.5–6.4.
Table 2 shows the results of percent drug content for all formulations. 
The drug content varies in the acceptable range. This was carried out 
in triplicate.
Table 2 shows the viscosity values obtained for all formulations. The 
viscosity directly depends on the polymeric content of formulation. 
The viscosity increases with increase in concentration of C934 P and 
decreases with PEG 6000.
In vitro study
The in vitro release kinetics were carried out for all formulations using 
pH 6.4 as diffusion medium. It was found that a concentration of PEG 
6000 increases drug release increase as it act as release enhancer and 
mucoadhesive polymer decreases drug release. The response surface 
plot studied for the response (Y3), i.e., percent drug release, shown in 
Fig. 2c, showed the significant effect of variables on the response (Y3).
In vitro permeation studies
Formulation F2 demonstrated good drug release profile with favorable 
gelation and viscosities. Hence, the formulation F2 was chosen as an 
optimized formulation to observe the permeation of drug through 
nasal mucosa. In vitro permeation was observed for aqueous drug 
solution and formulation F2. The drug release was estimated using UV 
spectrophotometer at 272 nm. It was observed that drug release from 
the optimized formulation F2 was 93.74% at the end of 6 h and from 
aqueous solution was 86.81% within 3 h as shown in Fig. 3.
The release of MCH from the gel formulation was found to be up to 6 h 
and that may be due to the inverse relationship between viscosity and 
drug release.
Histopathological evaluation of mucosa
The microscopic observation specifies that the optimized formulation 
has no any significant effect on the microscopic structure of mucosa as 
shown in Fig. 4a-c. No any cell destruction or removal of the epithelium 
from the nasal mucosa was observed after application of formulation 
and buffer pH 6.4.
Multiple regression analysis for 32 factorial design
The responses obtained from factorial design were subjected to multiple 
regression analysis. Responses studied were GT (°C), mucoadhesive 
strength (dyne/cm2), and drug release (%).
The polynomial form for the response (Y1) GT (°C),
Y1 = 23.34+36.89X1−5.14X2+2.68X1X2+4.00X12−32.00X22 1
The polynomial form for the response (Y2) mucoadhesive strength 
(dyne/cm2),
Y2 = 89.44+264.11X1+23.71X2+360.15X1X2+89.23X12+34.62X22 2
The polynomial form for the response (Y3) drug release (%),
Y3 = 89.44+6.29X1+9.33 X2−3.88 X1X2−2.99X12+0.085X22 3
Fig. 1: Fourier transform infrared spectrum of metoclopramide hydrochloride and optimized batch F2
Table 1: Factors and levels in the optimization of in situ gel 
formulation
Independent variables Levels
(−1) Lower (0) Middle (+1) Upper
C934P (X1) %w/v 0.25 0.5 0.75
PEG 6000 (X2) %w/v 0.5 1 1.5
C934P: Carbopol 934P; PEG 6000: Polyethylene glycol 6000. Levels in columns 
indicate quantities.
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Fig. 3: Percent cumulative release of optimized batch and plain drug through nasal mucosa
Fig. 2: Response surface plot (a) gelation temperature, (b) mucoadhesive strength, and (c) % drug release
a b
c
Table 2: Evaluation parameters of formulation
Batch Gelation  Temperature 
(GT) (oC)
Gel melting Temperature
(GMT) (oC)  
pH Drug Content (%) Mucoadhesive 
strength (dyne/cm2)
Viscosity(cps)
F1 32.70±1.10 41.21±1.25 5.2±0.1 99.89±1.27 653.81±2.30 1505±2.89
F2 34.71±1.11 40.44±1.19 5.3±0.1 100.6±1.21 807.12±3.45 1218±1.42
F3 28.62±1.20 45.22±1.11 5.2±0.1 96.12±1.29 474.35±1.10 921±1.15
F4 33.31±1.22 41.34±1.13 5.1±0.1 94.90±1.20 1010.89±2.75 1120±2.50
F5 32.10±2.11 38.77±1.11 5.1±0.1 96.70±1.24 1189.43±2.70 1365±3.25
F6 29.32±1.14 42.46±2.00 5.5±0.1 96.76±1.26 743.87±1.78 930±1.20
F7 35.31±1.21 38.55±1.13 5.3±0.1 94.25±1.27 680.56±1.62 1284±3.06
F8 35.30±1.10 39.23±1.12 5.6±0.1 91.22±1.21 1485.82±3.16 1210±1.78
F9 31.73±1.19 38.24±1.19 5.6±0.1 103.55±1.20 921.63±2.88 1125±2.60
Mean ± S.D.; n=3
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Analytical procedure
MS tune of MCH is shown in Fig. 5. Figure indicates m/z ratio for 
metoclopramide parent ion at 227.2 and m/z ratio for metoclopramide 
daughter ion at 300.2.
Bioavailability study
Pharmacokinetic parameters were calculated from the observed 
plasma concentration time profiles. The values of Cmax, maximum time 
taken to attend plasma concentration (Tmax), and AUC0-4 (ng.h/ml) are 
shown in Fig. 6. MCH attained a high concentration of 23.50±5.02 ng/ml 
and decreases after 120 min for nasal in situ gel. For i.v. marketed 
preparation, after 60 min, Cmax was 45.70±6.12 ng/ml. It was observed 
that concentration of drug in plasma (Cmax) was achieved twice higher 
by i.v. as compared to nasal in situ gel. The Tmax was 120 min and 60 min 
for nasal in situ gel and i.v., respectively. The AUC0-4 was 2716±4.62 and 
2874±1.08 ng.h/ml  for nasal in situ gel and i.v. solution, respectively, 
but the bioavailability for nasal in situ gel was found to be 94.50%.
DISCUSSION
The prepared formulations were colourless, viscous with no any 
aggregations and grittiness[14]. The physiological range of the nasal 
mucosa temperature lies between 32 and 35°C [15]. Our target was 
to develop a nasal mucoadhesive thermoreversible gel with a phase 
transition temperature in the range 25–34°C, which would remain liquid 
at room temperature and gel after nasal administration. P407 decreases 
GT as its concentration increases because as temperature increases, the 
number of micelles formed increasesas a consequence of the negative 
coefficient of solubility of block copolymer micelles. Sooner or later, 
the micelles become immmobile and a gel is formed [16]. The pH of 
the formulation was kept in the range of 5.1±0.1 to 5.6±0.1 to avoid 
irritation to the nasal mucosa, and other-related changes by formulation 
could produce. A Viscosity of formulation increases in the presence 
of mucoadhesive polymer and decreases with PEG 6000. Response 
surface plot, regression equation, and p-values showed that C934P had 
significant effect on GT and mucoadhesive strength. It lowers GT due to 
its ability to bind with polyethylene oxide chain present in poloxamer 
molecules. This in turn promotes dehydration and causing an increase 
in entanglement of nearby molecules [10]. But the addition of PEG 6000 
increases GT due to an interference of PEG with a process of micellar 
association of poloxamer chain [17]. Since PEG 6000 act as release 
enhancer but its addition was discontinued when the GT of in-situ gel 
approaches 34°C. The mucoadhesive strength increases with increasing 
concentration of C934P. This acts as a good mucoadhesive polymer due 
to the presence of a high percentage of (58–68%) carboxylic group 
[18]. Hydrogen bonding is favored in the presence of these groups with 
sugar residue from oligosaccharide chains in the mucus membrane. 
This further results in the creation of strong linkage between polymer 
and mucus membrane. Hence, higher mucoadhesive strength leads to 
prolonged withholding that could overcome mucocilliary clearance 
and thereby increased absorption across mucosal tissue. This in line 
improves bioavailability. PEG 6000 and C934P had a significant effect 
on metoclopramide release. There was a decrease in drug release with 
C934P increase as a viscosity of formulation increases since C934P 
leads to acid-base interaction and formed a reservior of ion pair of 
the carbopol metoclopramide hydrogel which could contribute slow 
drug release [19]. However, PEG 6000 shows release enhancing effect 
due to its higher water solubility and lowering viscosity effect [20]. 
Fig. 5: Mass spectrometry tune of metoclopramide hydrochloride
Fig. 4: Histopathology of nasal mucosa (a) nasal mucosa treated 
with optimized in situ gel formulation, (b) nasal mucosa treated 
with phosphate buffer pH 6.4 (negative control), (c) nasal mucosa 
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Similar results were obtained by Thanvi DA [8]. Some formulations 
showed Fickian and some showed non-Fickian (anamolous) release 
kinetic revealed by (n) values between 0.26 and 0.94, which indicate 
that release of MCH followed diffusion and coupled erosion diffusion 
mechanism [21].
The use of mucoadhesive formulation was not only limited to their 
bioadhesive efficacy but safety is also concerned. Hence, it was 
necessary to investigate the safety of optimized formulation. The 
histopathological study revealed the safety of tested formula. An ex vivo 
study was performed to observe permeation of drug through the nasal 
mucosa. The release of MCH from gel formulation was found lower as 
compared with aqueous drug solution. This can be explained with the 
inverse relation between viscosity and drug release. A Viscosity of the 
formulation influences the release of MCH from gel formulation [5].
The pharmacokinetics of the optimized formulation, F2, were studied 
in rabbits. The marketed preparation through i.v. administration was 
decided to select for comparison because marketed preparations are 
already clinically proven, and maximum AUC is obatined by i.v. route. 
Thereby, we can decide really where the prepared in situ gel stands for 
systemic bioavailability by nasal route. From pharmacokinetic studies, 
it can be concluded that in situ gel formulation was capable to release 
the drug in systemic circulation since bioavailability by nasal route 
was found to be 94.50%, which is closer to i.v. route [13]. The point to 
be noted here is that the values of AUC are comparable for both nasal 
and i.v. route though there is a difference in the Tmax and Cmax of both 
the formulations. Although the physical nature of the formulation is 
different (in situ gel and solution) and route of administration is also 
different (nasal and i.v., respectively), the bioavailability is likely to be 
produced the same. Fig. 6 clear cut states that the duration of the action 
is greater for in situ gel by nasal route than solution by i.v. route. This 
is because the significant steady-state concentration is found available 
in the blood for a considerable time. This is supported by the slow 
elimination rate of drug observed in the curve through in situ gel. The 
steady-state concentration or a plateau observed in the curve indicates 
that the in situ gel was in contact with a nasal mucosa of rabbit for a 
longer time incapacitating a mucociliary clearance successfully. Noha et 
al. reported earlier that bioavailability of MCH was 40-80 % if gel of MCH 
administered orally. And also it has been proved that bioavailability can 
be improved if MCH is formulated into an in-situ gel and administer 
nasally. Therefore, the order of bioavailability is i.v. > nasal> oral. These 
findings are in full support with the findings mentioned by  Duchateau 
et al. [22]. According to them, the order of bioavailability for alprenolol 
was the same.
CONCLUSION
The Mucoadhesive thermo reversible in situ gel prepared with P407 
and C934P can be successfully used to deliver MCH effectively by nasal 
route. The AUC for nasal in situ gel was comparable with the marketed 
solution of MCH administered intravenously.
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